Biocon receives US FDA approval for Pebrilzo injection
PEBRILZO further strengthens Biocon’s oncology portfolio, now totaling five biosimilar therapies for cancer in the United States
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.